3 results match your criteria: "Cancer Center GF Leclerc[Affiliation]"
J Thorac Dis
June 2022
Department of Medical Oncology, Cancer Center GF Leclerc, Dijon, France.
Background: The best management for rare epidermal growth factor receptor (EGFR) mutations in advanced non-small cell lung carcinoma (NSCLC) remains uncertain. The literature indicates that response to usual treatment could differ in certain subgroups such as exon 20 insertion/duplication (E20ID), other single uncommon mutation (OSUM), and EGFR complex mutation (ECM).
Methods: In this observational, regional, multi-center, retrospective study, we gathered data on uncommon EGFR mutations in NSCLC from 2007 to 2021.
Am J Case Rep
March 2022
Department of Medical Oncology, Cancer Center GF Leclerc, Dijon, France.
BACKGROUND Small cell carcinoma (SCC) is usually aggressive and associated with a poor prognosis. This type of cancer is rarely found in extra-pulmonary or digestive-tract locations. This report describes an unusual presentation in terms of clinical symptoms and primary location (even among head and neck presentations), and unexpected occupational exposure.
View Article and Find Full Text PDFCancer Radiother
July 2020
Department of radiation oncology, Cancer Center GF Leclerc, Dijon, France.
Purpose: The present study evaluated the outcomes of concurrent weekly docetaxel and platinum-based drug doublet in association with concurrent thoracic radiotherapy (TR) in the curative treatment of stage III locally advanced non-small-cell lung cancer (NSCLC).
Patients And Methods: Patients with stage IIIA/B NSCLC were retrospectively included. Patients received weekly docetaxel and either cisplatin or carboplatin intravenous injections during concurrent TR (60 to 66Gy).